STOCK TITAN

Nextcure Inc - NXTC STOCK NEWS

Welcome to our dedicated news page for Nextcure (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nextcure's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nextcure's position in the market.

Rhea-AI Summary
NextCure, Inc. provided a business update and reported Q3 2023 financial results. Updates on clinical programs, including Phase 1b trials of NC410 and NC762, and a Phase 1a operational update for NC525 are expected by year end. The company has approximately $118 million in cash, which is expected to fund operations into mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
-
Rhea-AI Summary
NextCure presents preclinical data on potential treatment for osteogenesis imperfecta at ASBMR Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
NextCure presents preclinical data on NC181, a novel antibody targeting ApoE4 for Alzheimer's disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
Rhea-AI Summary
NextCure presents Phase 2 clinical data at lung cancer conference, demonstrating clinical benefit in patients with advanced NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary
NextCure announces publication of review article highlighting the need for targeting tumor collagen in the tumor microenvironment to enhance anti-tumor immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
-
Rhea-AI Summary
NextCure presents preclinical data on anti-S15 antibody's potential to treat bone loss after spinal cord injury
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
Rhea-AI Summary
NextCure to participate in fireside chat at H.C. Wainwright Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
-
Rhea-AI Summary
NextCure, a clinical-stage biopharmaceutical company, will present at the JMP Securities Life Sciences Conference in New York City on May 16th at 11:30 am ET. A live audio webcast will be available on the company's website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.41%
Tags
conferences
Nextcure Inc

Nasdaq:NXTC

NXTC Rankings

NXTC Stock Data

53.57M
20.76M
8.84%
50.25%
3.56%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Beltsville

About NXTC

nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col